Latest Posts


Jun 23

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to...
Read More


Feb 23

AI supports targeted therapy recommendations fortumor diseases – BMBF funds joint research projectat University Medical Center Mainz with 2.53 millionEuros

The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More

Blockchain and AI-based Platform iPlexus to Revolutionize Drug Discovery

Innoplexus AG announced a revolutionary update is coming soon to their iPlexus platform that will harness the power of blockchain technology and artificial intelligence to weed out wastefulness in early-stage drug discovery. iPlexus is a one-stop deep data ocean of relevant information for the pharmaceutical industry. It uses the power of Blockchain and AI to revolutionize the drug discovery and research process.

Co-founder and CEO of Innoplexus AG, Gunjan Bhardwaj, explained more about their vision for the new iPlexus, “Our mission at Innoplexus is to democratize the drug discovery process. We believe that cutting-edge technologies like AI and blockchain are the key to making this possible. After over 6 months of research, we believe that the new iPlexus is a major step forward for the preclinical trial industry and will solve many of the problems that are slowing the industry down. By overcoming these challenges, we will make drug discovery more efficient and bring down the consumer price of drugs.”

The launch date is scheduled for June 30, 2018. Blockchain and AI-based iPlexus intends to overcome data silos to make drug discovery more efficient. iPlexus will help in intelligence and insights throughout pre-clinical, clinical, regulatory and commercial phases of drug development in a quick, crisp and summarized snapshot with various profound dive opportunities.

The platform has the potential to bolster the healthcare system through practical innovation acceleration and equal opportunities. It would incentivize smaller researchers to share even failed experimental data. Data enrichment would, in turn, lead to data innovation and the innovation dynamics would be beneficial for the patients.

The original article was published on BCFocus.

Featured News

New app for cancer patients

Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…